Natera, INC Form 4 insider transactions

Jonathan Sheena, a Director of Natera, Inc., sold 18,064 shares of common stock on September 23, 2026.

Solomon Moshkevich, PRESIDENT, CLINICALDIAGNOSTICS of Natera, Inc., reported a transaction in 945 shares of common stock on September 16, 2026.

Jonathan Sheena, a Director of Natera, Inc., sold 9,150 shares of common stock on September 15, 2026.

Matthew Rabinowitz, EXECUTIVE CHAIRMAN and a Director of Natera, Inc., sold 102,000 shares of common stock on September 14, 2026.

Matthew Rabinowitz, EXECUTIVE CHAIRMAN and a Director of Natera, Inc., sold 50,000 shares of common stock on September 11, 2026.

Solomon Moshkevich, PRESIDENT, CLINICALDIAGNOSTICS of Natera, Inc., sold 18,160 shares of common stock on September 1, 2026.

Steven Leonard Chapman, CEO AND PRESIDENT and a Director of Natera, Inc., sold 1,698 shares of common stock on September 1, 2026 for $320.99 per share.

John Fesko, PRESIDENT, CHIEF BUS. OFFICER of Natera, Inc., sold 6,517 shares of common stock on August 6, 2026 for $321.53 per share.

Jonathan Sheena, a Director of Natera, Inc., sold 6,000 shares of common stock on August 10, 2026 for $325.32 per share.

Matthew Rabinowitz, EXECUTIVE CHAIRMAN and a Director of Natera, Inc., sold 2,000 shares of common stock on August 7, 2026 for $320.90 per share.

Jonathan Sheena, a Director of Natera, Inc., sold 9,150 shares of common stock on August 7, 2026.

Michael Burkes Brophy, CHIEF FINANCIAL OFFICER of Natera, Inc., sold 795 shares of common stock on August 3, 2026.

Steven Leonard Chapman, CEO AND PRESIDENT and a Director of Natera, Inc., sold 3,076 shares of common stock on August 3, 2026.

John Fesko, PRESIDENT, CHIEF BUS. OFFICER of Natera, Inc., sold 295 shares of common stock on August 3, 2026 for $267.99 per share.

Solomon Moshkevich, PRESIDENT, CLINICALDIAGNOSTICS of Natera, Inc., sold 3,410 shares of common stock on August 3, 2026.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., sold 334 shares of common stock on August 3, 2026 for $267.99 per share.

Matthew Rabinowitz, EXECUTIVE CHAIRMAN and a Director of Natera, Inc., sold 731 shares of common stock on August 3, 2026 for $267.99 per share.

Jonathan Sheena, a Director of Natera, Inc., sold 109 shares of common stock on August 3, 2026 for $267.99 per share.

Jonathan Sheena, a Director of Natera, Inc., sold 479 shares of common stock on July 27, 2026.

Matthew Rabinowitz, EXECUTIVE CHAIRMAN and a Director of Natera, Inc., sold 1,718 shares of common stock on July 27, 2026 for $260.49 per share.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., sold 1,887 shares of common stock on July 27, 2026.

Solomon Moshkevich, PRESIDENT, CLINICALDIAGNOSTICS of Natera, Inc., sold 2,214 shares of common stock on July 27, 2026.

John Fesko, PRESIDENT, CHIEF BUS. OFFICER of Natera, Inc., sold 1,713 shares of common stock on July 27, 2026.

Steven Leonard Chapman, CEO AND PRESIDENT and a Director of Natera, Inc., sold 5,770 shares of common stock on July 27, 2026.

Michael Burkes Brophy, CHIEF FINANCIAL OFFICER of Natera, Inc., sold 5,064 shares of common stock on July 27, 2026.

Jonathan Sheena, a Director of Natera, Inc., sold 1,500 shares of common stock on July 15, 2026.

Rowan E Chapman, a Director of Natera, Inc., sold 135 shares of common stock on July 15, 2026 for $274.82 per share.

Jonathan Sheena, a Director of Natera, Inc., sold 3,150 shares of common stock on July 13, 2026.

Natera, Inc. Executive Chairman Matthew Rabinowitz has sold 1,000 shares of common stock, valued at approximately $280 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Natera, Inc. reports that its SEC and Chief Legal Officer, Daniel Rabinowitz, sold a total of 17,994 shares of common stock on July 1, 2026, through a pre-arranged Rule 10b5-1 trading plan.